Impact of dose-difference in comparator arms among clinical trials on treatment effect size in a network meta-analysis: A case of first-line therapies in chronic lymphocytic leukemia (CLL). Poster presentation at the International Workshop on Chronic Lymphocytic Leukemia.
Comparative safety analysis of currently approved anti-CD20 monoclonal antibodies for first line treatment of chronic lymphocytic leukemia (CLL). Poster presentation at the International Workshop on Chronic Lymphocytic Leukemi
Disease burden and treatment landscape in Duchenne Muscular Dystrophy (DMD) in the United States.
Clinical and economic assessment of diffuse large b-cell lymphoma (DLBCL) therapies using a proprietary value assessment platform.
Use of intermediate clinical endpoints (ICE) as a primary efficacy endpoint in malignant melanoma.
Targeted literature review of adherence to therapies in cystic fibrosis (CF).
Clinical and economic burden of acquired hemophilia (AH) among hospitalized patients in the US using healthcare cost and utilization project (HCUP).
Conceptualization of an Excel-based indication-specific pricing (ISP) model to assess potential savings to a U.S. Health plan.
Identifying the highest business opportunity for future development among key patient subgroups in non-small cell lung cancer (NSCLC).
Burden of Merkel cell carcinoma: a targeted literature review.
